FERROUS CITRATE FE 59
LOE Approachingferrous citrate, fe-59
NDAINJECTIONINJECTABLEPriority Review
Approved
Dec 1973
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Priority Review
Drug data last refreshed 16h ago · AI intelligence enriched 21h ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
Ferrous Citrate Fe-59 is a radioactive iron isotope diagnostic agent administered by injection to evaluate iron metabolism and red blood cell production. This nuclear medicine product is used to assess iron kinetics and measure red cell mass in patients with suspected iron metabolism disorders or hematologic conditions.
LOE Approaching
Product is approaching loss of exclusivity with minimal current linked opportunities; commercial teams are likely focused on market defense and cost management rather than expansion.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Zero linked job openings reflect the legacy status and niche market of this diagnostic product. Career opportunities are limited to maintenance-mode roles in compliance, quality, and regulatory affairs rather than growth-oriented positions.
Regulatory Affairs SpecialistQuality Assurance Specialist
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.